Latest news
Ten Years of MS Data Make Delay Harder to Defend
A decade of OPERA follow-up shows durable relapse and disability control with ocrelizumab, while patients who started high-efficacy therapy later never fully caught up. The escalation debate now carries a long-term cost.
Severe preeclampsia may leave a measurable signature in the fetal heart
IPM Brief – Issue 37 | The body has a veto
One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.
Schizophrenia Gets a Five-Day Brain-Stimulation Signal
The Mystery Patient Found The Gaps
Europe is building the infrastructure to decide which cardiovascular AI can be trusted
Fasted cardio burns more fat during exercise, but the long-term advantage disappears
Skin Cancer AI Has Crossed a Line: It Is Discharging Patients on Its Own
Genomics Is Becoming an Acute Neurology Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.